In Deal With Medicines Patent Pool, Bristol-Myers Squibb Agrees To Allow Generic Versions Of HCV Treatment To Be Sold In LMICs

Reuters: Bristol-Myers signs deal with U.N. group for generic hep C drug
“A United Nations-backed organization working to cut the price of HIV drugs said it had signed a deal with Bristol-Myers Squibb Co. to allow generic versions of the company’s hepatitis C drug to be sold in 112 low- and middle-income countries. … The Medicines Patent Pool said on Monday that Daklinza would now be available to nearly two-thirds of people affected by the disease in low- and middle-income countries…” (Nathan, 11/23).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

The Henry J. Kaiser Family Foundation Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KaiserFamilyFoundation | twitter.com/kff

Filling the need for trusted information on national health issues, the Kaiser Family Foundation is a nonprofit organization based in San Francisco, California.